Approval from Colombia's INVIMA will accelerate growth in Colombia, by registering our product and getting regular supplies
Commercial terms include research funding and milestones and/or royalty payments to Evotec based on the success of the program
The campaign marks an important milestone in its journey within the pharmaceutical manufacturing industry
NM5072 is an anti-Properdin antibody that selectively blocks the alternative pathway while maintaining the integrity of the classical pathway required for fending off infections
Longest survival follow-up ever reported for immunotherapy treatment in this setting
US FDA and EMA accepted filings based on the data from OCARINA II, with EU approval anticipated mid-2024 and U.S. approval anticipated September 2024
Global Phase-3 study initiation expected in the second half of 2024
KRKA holds 51% and Laurus Labs holds 49% shareholding
_256_384.jpg)
This facility manufactures APIs & formulations of oncology and non-oncology products.
Subscribe To Our Newsletter & Stay Updated
